Analysis of cytotoxic T-lymphocyte-associated antigen-4 and MMP-9 genes’ methylation and their expression profiles with risk of non-alcoholic fatty liver disease

Dor Mohammad Kordi Tamandani, Mohammad Hashemi¹, Sara Shafiepour²

Department of Biology, University of Sistan and Baluchestan, Zahedan, Iran, ¹Department of Clinical Biochemistry, Zahedan University of Medical Sciences, Zahedan, Iran, ²Department of Internal Medicine, School of Medicine, Karman University of Medical Sciences, Karman, Iran

OBJECTIVE: To investigate the effect of promoter methylation of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene and matrix metalloproteinases (MMPs) on the risk of non-alcoholic fatty liver disease (NAFLD).

MATERIALS AND METHODS: CTLA-4 and MMP-9 promoter methylation were investigated using a methylation-specific polymerase chain reaction (MS-PCR) in blood samples taken from 80 NAFLD individuals and 95 healthy controls. The expression levels of CTLA-4 and MMP-9 were also assessed in 10 blood and 9 liver tissues mRNA samples from NAFLD patients. These cases were compared to the blood (n=10) samples of healthy controls with real-time quantitative reverse transcriptase PCR.

RESULTS: No significant relationship was found for methylation of CTLA-4 and MMP-9 between cases and controls. The relative expression of CTLA-4 and MMP-9 mRNA in NAFLD was not significantly different compared to healthy control samples.

CONCLUSION: For the first time, our outcomes indicate that the methylation status of CTLA-4 and MMP-9 genes has no significant function on the process of NAFLD.

Key words: Cytotoxic T-lymphocyte-associated antigen-4, expression, gene, methylation, matrix metalloproteinases-9, non-alcoholic fatty liver disease

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease worldwide.¹ It also has been found to be a significant risk factor for expansion of primary liver cancer and liver-associated mortality and morbidity.²,³ NAFLD refers to a spectrum of histological findings, ranging from simple and reversible steatosis to steatohepatitis and cirrhosis, and is diagnosed after ruling out other causes—in particular, alcoholic liver disease (ALD).⁴ In addition to a higher prevalence of NAFLD in patients with obesity, metabolic syndrome, and type 2 diabetes, it also can be induced by a variety of genetic variations.⁵ However, the data is sparser regarding genetic and epigenetic variations on the etiology of NAFLD. Understanding these types of alterations would have a critical effect on the clinical practice and management of disease.⁶ Matrix metalloproteinases (MMPs) are a family of proteases with roles in the development and invasion of various cancers, including degrading components of the extracellular matrix, which paves the way for the transportation of tumor cells to other tissues.⁷ The MMP-9 gene is placed at chromosomal location 20q13.2, and its exact expression mechanisms are unknown.⁸ A few studies have evaluated the involvement of these genetic variations in development of chronic liver disease.⁹
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is a single-spanning membrane protein, the gene for which is located on chromosome 2q33. This protein is positioned on a T-cell surface molecule which interacts computationally with the co-stimulatory molecule CD28 and plays a major role in peripheral control of the immune response. It seems likely that the decreased expression of CTLA-4 might cause autoimmune T-cell clonal proliferation. Several studies have shown that the dysfunction of CTLA-4 is connected to autoimmune disorders. This study analyzed the link between the promoter hypermethylation of MMP-9 and CTLA-4 genes and their expression in blood samples of patients with NAFLD disease in a group of patients in South Eastern Iran.

Materials and Methods

Study subjects and specimens

This case-control study was performed on 80 patients with confirmed NAFLD and 95 healthy subjects. Samples were collected in the Ali-Ebn-Abi Taleb hospital from 2008 to 2010. Exclusion criteria were: Patients with other known causes of liver disease, including viral hepatitis B and C; hemochromatosis; Wilson disease; autoimmune liver diseases; a history of alcohol consumption of more than 100 g/week; and chronic drug use. Individuals who were overweight or (defined as a body mass index [BMI] >25 kg/m²) had type 2 diabetes or hyperlipemia and an abnormal liver function test participated in the study. Laboratory assays encompassed fasting glucose, insulin, total cholesterol, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol, triglycerides, iron, TIBC, ferritin, ceruloplasmin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, alkaline phosphatase, bilirubin, HBS-Ag, HBC-Ab, LKM1 antibody, HCV antibody, antismooth muscle antibody and antimitochondrial antibody, and antinuclear antibody, collected after a 12-h overnight fast. Hepatic ultrasonography scanning was performed in all participants by an experienced radiologist who was blinded to participants’ details. The diagnosis of NASFLD was performed according to the clinical setting, sonographic, and laboratory findings, because the patients did not agree to undergo liver biopsy. Normal subjects were selected from the Zahedan population who participated in the metabolic syndrome project and had normal blood pressure, normal lipid profiles, normal blood glucose, normal BMIs, normal waist circumference, and no history of systematic disease. Demographic and clinical data on cases and controls are shown in Table 1. The lab work for the analysis of gene methylation was done in parallel for cases and controls.

DNA extraction and methylation analysis

DNA was extracted from whole blood using the phenol-chloroform extraction method; then, 2 μg of purified DNA were converted using sodium bisulfite as previously described. Variations in sequences of DNA after treatment by sodium bisulfate were identified by Methylation-specific PCR (MSP). The primer sequence and PCR conditions are listed in Table 2. Each MSP reaction included: 80 ng of bisulphate-converted DNA, 1 μM of each primer, and 2U Hot Start Taq (Cat, No: #EP0602, Fermentase). Finally, PCR products were analyzed by electrophoresis on 3% agarose gel stained with ethidium bromide. Positive controls (in vitro methylated and bisulfite-treated human placental DNA) and negative controls (no template) were included in all reactions.

| Variables  | Controls N=95 | Cases N=80 | P value |
|------------|---------------|------------|---------|
| Age (year) | 37.85±14.77   | 40.82±11.74| 0.144   |
| Weight (kg)| 65.60±15.14   | 82.29±11.89| <0.001 |
| Height (cm)| 161.29±9.39   | 165.79±8.83| 0.003   |
| BMI (kg/m²)| 25.22±5.25    | 30.01±4.21 | <0.001 |
| AST (IU/L) | 20.89±3.48    | 47.69±28.61| <0.001 |
| ALT (IU/L) | 19.40±2.52    | 71.60±47.34| <0.001 |
| FBG (mg/dL)| 88.58±20.06   | 110.24±37.71| <0.001 |
| TG (mg/dL) | 167.11±131.06 | 207.22±119.80| 0.051   |
| Total chol (mg/dL)| 178.50±37.02 | 200.82±38.20| <0.001 |
| HDL-C (mg/dL) | 45.02±6.80 | 43.24±8.42 | 0.156   |
| LDL-C (mg/dL) | 99.27±30.90 | 108.73±26.92| 0.046   |

BMI: Body mass index, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, HDL: High density lipoprotein, LDL: Low density lipoprotein, FBG: Fast blood glucose, TG: Triglyceride, Chol: Cholesterol
Extraction of RNA and reverse transcription

Overall RNA from blood and tissues was extracted using the High Pure RNA Isolation Kit (Cat No: 11828665001, Qiagen, Hilden, Germany and Cat No: 04823125001, High Pure FFPE). The RNA concentration was identified spectrophotometrically, and the integrity of all samples was confirmed by electrophoresis in ethidium bromide-stained 1% agarose gel. First-strand cDNA was synthesized from 1 μg of total RNA using the First Strand cDNA Synthesis Kit (Cat No: K1611, Fermentase) according to the manufacturer’s instructions.

Quantitative real-time polymerase chain reaction with SYBR green

Real-time polymerase chain reaction (RT-PCR) was performed in order to set up a quantitative association between PCR products obtained from the target gene and a housekeeping gene (RNA 18s). Quantitative RT-PCR assays were performed with the RT-PCR System (7300, Applied Biosystems) using SYBR green fluorescence. PCR amplification was done in 20 μL of the reaction mixture containing 3 μL of cDNA, 10 μL SYBR green, 2 μL of both primers (forward and reverse), and 5 μL of H₂O. The sequences of the primers used for this purpose can be found in Table 2.

Statistical analysis

Analysis of data was based on the multivariate logistic regression analysis for estimation of methylation status in groups, and the Mann-Whitney test was used for examination of gene expression data. The level of significance was set at $P < 0.05$. 

Results

The outcomes of the MMP-9 and CTLA-4 genes’ methylation between cases and controls are given in Tables 3 and 4. As indicated, the CTLA-4 gene was 85.0% methylated in NAFLD patients and 85.26% methylated in healthy individuals. Statistically, this variation is not significant between healthy controls and patients. A similar statistical correlation has been found for the MMP-9 gene, which was 85.26% methylated in normal individuals and 88.75% methylated in unhealthy individuals.

CTLA-4 and MMP-9 gene expression

The differences between CTLA-4 and MMP-9 mRNA levels were assayed in 10 NAFLD (10 blood and 9 liver tissues) and 10 normal blood samples. As shown in Tables 5 and 6, there was no statistically significant assessment for relative gene expression in a comparison between cases and controls for the CTLA-4 and MMP-9 genes. Further studies utilizing larger sample sizes are necessary to achieve a conclusion regarding the effect of altered gene expression of CTLA-4 and MMP-9 genes in NAFLD.

Discussion

NAFLD has become the leading cause of referral to hepatology clinics and is a major future research field in internal medicine. Data from interethnic differences and family studies have shown that genetic factors may have a critical function in the causation of NAFLD. However,
data regarding gene association studies for patients with NAFLD is sparse. Determining genetic and epigenetic risk factors that predict the level of fibrosis progression or susceptibility to viral agents may be useful for better management of patients in an individual way.\(^{[20]}\) Evidence for the involvement of genetic factors in the development of advanced fibrosis in NAFLD has been extracted from family clustering studies.\(^{[21]}\) Day et al. have reported that genetic susceptibility plays a key role in alcohol-induced liver disease.\(^{[22]}\) In eukaryotics, gene expression is controlled by many mechanisms; DNA methylation is a general epigenetic signaling tool which cells utilize to lock genes in the "off" position.\(^{[23]}\) The majority of DNA methyl regions were located on promoter sites, which show various patterns of expression, depending on the amount of methylated sites.\(^{[24]}\) The finding of methylated DNA sequences in serum has been recommended as a potentially valuable biomarker for preclinical diagnosis of malignant lesions.\(^{[25]}\)

In fact, numerous studies of hepatocellular carcinoma have revealed that methylated p15, p16, and RASSF1A sequences are present in serum at the time of cancer diagnosis.\(^{[24,26,27]}\) CTLA-4 encodes a T-cell receptor that mediates T-cell apoptosis, which has a significant effect on genetic susceptibility to autoimmune diseases, such as type 1 diabetes.\(^{[26,28]}\) Xia Zhao et al.\(^{[29]}\) have suggested that the susceptibility to variants of the CTLA-4 gene vary between the different geographic populations with Graves’ disease.\(^{[30]}\)

Increased levels of plasma MMP-9 have been found in a variety of malignant cancers, such as colon cancer, lung cancer, breast cancer, and hepatocellular carcinoma.\(^{[31-34]}\) Matsumura et al. indicated that the T-allele in the MMP-9 promoter is associated with the invasive phenotype of gastric cancer.\(^{[35]}\) Certain other studies suggested that plasma MMP-9 may play an important role in the progression of breast cancer.\(^{[36,37]}\)

### Conclusion

Our study provides data that promoter methylation of CTLA-4 and MMP-9 have no significant effect on the etiology of NAFLD. Still, data from gene involvement studies in patients with NAFLD are uncertain. Most available results were performed in small cohorts of patients carrying the risk factors for the disease. The present report needs to be confirmed by a subsequent larger sample size and a number of other candidate genes that have been involved in NAFLD.

### Acknowledgment

This work was supported by research grants from the University of Sistan and Baluchistan and Zahedan University of Medical Sciences.
References

1. Mehta K, Van Thiel DH, Shah N, Mobaran S. Nonalcoholic fatty liver disease: Pathogenesis and the role of antioxidants. Nutr Rev 2002;60:289-93.
2. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-54.
3. Bullock RE, Zaltoum AM, Aithal GP, Ryder SD, Beckham IH, Lobo DN. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J Hepatol 2004;41:685-6.
4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006;43:S99-S112.
5. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
6. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009;50:S412-6.
7. Jodele S, Chantrain CF, Blavier L, Lutzko C, Crooks GM, Jodele S, Chantrain CF, Blavier L, Lutzko C, Crooks GM, Hamodrakas SJ. No evidence for association of CTLA-4 gene polymorphism at position 318T/G with early lethality in mice deficient in Ctla-4. Science 1995;270:985-8.
8. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, Waterhouse P, Penninger JM, Timms E, Wakeham A, Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Bartolocci F, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
9. Kordi-Tamandani DM, Moazeni-Roodi AK, Rigi-Ladiz MA, Hashemi M, Birjandian E, Torkamanzehi A. Promoter hypermethylation and expression profile of MGMT and CDH1 genes in oral cavity cancer. Arch Oral Biol 2010;55:809-14.
10. Osterreicher CH, Brenner DA. The genetics of nonalcoholic fatty liver disease. Ann Hepatol 2007;6:83-8.
11. Ghaderian SM, Akbarzadeh Najr, Tabatabaei Panah AS. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis 2010;21:330-5.
12. Grove J, Daly AK, Bassendine MF, Gilvary E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000;46:540-5.
13. Phillips JM, Goodman JI. Identification of genes that may play critical roles in phenobarbital (PB)-induced liver tumorigenesis due to altered DNA methylation. Toxicol Sci 2008;104:86-99.
TIMP-2 - Complex or TIMP-1 corrected in stage corrected I-III lung carcinoma. Cancer Lett 2006;236:125-32.
35. Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, et al. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 2005;131:19-25.
36. Liu ET, Kuznetsov VA, Miller LD. In the pursuit of complexity: Systems medicine in cancer biology. Cancer Cell 2006;9:245-7.
37. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, et al. Circulating MMP2 and MMP9 in breast cancer – Potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006;119:1403-11.

Cite this article as: Tamandani DK, Hashemi M, Shafiepour S. Analysis of cytotoxic T-lymphocyte-associated antigen-4 and MMP-9 genes’ methylation and their expression profiles with risk of non-alcoholic fatty liver disease. Indian J Hum Genet 2013;19:144-9.
Source of Support: Supported by research grants from the University of Sistan and Baluchistan and Zahedan University of Medical Sciences., Conflict of Interest: None declared.